Rheumatoid arthritis - prognosis, predictors and outcome

POS0435

CHARACTERISTICS AND 6-MONTH OUTCOMES AMONG REAL-WORLD PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING UPADACITINIB: ANALYSIS FROM THE CORRONA REGISTRY

J. M. Kremer^{1,2}, N. Tundia³, R. McLean¹, T. Blachley¹, A. Maniccia³, D. A. Pappas^{1,4}, ¹Corrona, LLC, Waltham, United States of America; ²Albany Medical College, The Center for Rheumatology, Albany, United States of America; ³AbbVie Inc., North Chicago, United States of America; ⁴Columbia University, New York, United States of America

Background: Upadacitinib (UPA) has demonstrated efficacy in randomized controlled trials¹⁻³; however, few data are available from patients with rheumatoid arthritis (RA) who have been treated with UPA in real-world clinical practice.

Objectives: Describe the characteristics and 6-month outcomes in patients with RA initiating UPA in a real-world setting.

Methods: We identified adults with RA enrolled in the Corrona RA Registry through October 31, 2020 who initiated UPA during or after August 2019 and had a follow-up visit 6 (± 3) months after initiation of UPA. Descriptive statistics were used to summarize characteristics in all patients initiating UPA who had a 6-month follow-up visit. Outcomes (CDAI, modified HAQ-DI, pain, and fatigue) were described at the 6-month visit for all UPA initiators regardless of UPA use at 6 months and for the subset of patients who continued UPA through the 6-month visit. Patients who discontinued UPA before the 6-month visit were considered non-responders for dichotomous variables and were assigned the value at the time of discontinuation for continuous variables. Mean change from baseline in continuous variables was analyzed with one-sample *t* tests or one-sample Wilcoxon rank sum tests. Minimum clinically important difference (MCID) in HAQ-DI is defined as an improvement of 0.22 units or more. MCID in CDAI is an improvement of at least 2, 7, and 13 units for patients in low, moderate and severe disease at initiation, respectively. MCID for 100-point VAS is an improvement of ≥ 10 points. Percentages of patients achieving MCID thresholds were calculated.

Results: We identified 181 patients who initiated UPA and had a 6-month follow-up visit. Mean $\pm$ SD age was 58.6 $\pm$ 12.1 years, 81% were female. Patients had RA for a mean of 11.5 $\pm$ 9.8 years. At UPA initiation, 45% of patients were on monotherapy. Prior use of one or more TNFi and JAKi was 79% and 52%, respectively. Seventy-two percent of patients (n=130) initiated UPA as the third or higher line of therapy. Mean CDAI was 18.7 $\pm$ 11.6 and mean HAQ-DI was 1.1 $\pm$ 0.8 at initiation. Based on CDAI (n=155), 29%, 52%, and 15% of patients had high, moderate, and low disease activity, respectively; 4.5% were in remission at initiation. At 6 months (n=158), 22%, 39%, and 28% had high, moderate, and low disease activity, respectively; 11% were in remission. Among 138 initiators with valid CDAI measures at initiation and 6 months, mean change in CDAI was -4.8 $\pm$ 11.8, *P*<0.01. At 6 months, 46% (63/138) maintained and 39% (54/138) achieved improvement in any CDAI category. Improvements in other outcomes were significantly different from zero. Improvements $\geq$ MCID in CDAI, HAQ-DI, pain, and fatigue were achieved in 36–44% of UPA initiators. Improvements were similar, but larger in the subset of patients (n=122) who continued UPA through the 6-month visit (Table 1).

Conclusion: Among patients in the Corrona RA Registry, UPA is frequently started in those who failed multiple previous therapies. UPA initiators responded to therapy in the first 6 months with improvements in several disease activity measures including CDAI and HAQ-DI, as well as patient-reported pain and fatigue.

REFERENCES:

- [1] Fleischmann R. *Arthritis Rheumatol*. 2019;71:1788–800.
- [2] Smolen JS. *Lancet*. 2019;393:2303–11.
- [3] Burmester GR. *Lancet*. 2018;382:2505–12.

Acknowledgements: This study was sponsored by Corrona, LLC. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Pfizer, Regeneron, Roche, Sun, UCB, and Valeant. The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. No honoraria or payments were made for authorship.

Medical writing services were provided by Joann Hettasch of Fishawack Facilities Ltd., part of Fishawack Health, and funded by AbbVie.

Disclosure of Interests: Joel M Kremer Shareholder of: Corrona, Consultant of: AbbVie, Grant/research support from: AbbVie, Employee of: Corrona, Namita Tundia Shareholder of: AbbVie, Employee of: AbbVie, Robert McLean Employee

Table 1.

Outcomes at 6-month follow-up				
	All initiators (n=181)		Subset remaining on UPA (n=122)	
	n	Value ^a	n	Value ^a
Remission (CDAI <2.8)	158	18 (11)	105	12 (11)
Low (CDAI $\geq$ 2.8 and <10)	158	44 (28)	105	38 (36)
Moderate (CDAI $\geq$ 10 and <22)	158	62 (39)	105	36 (34)
High (CDAI $\geq$ 22)	158	34 (22)	105	19 (18)
Improvement in any CDAI category	138	54 (39)	89	40 (45)
Maintenance of CDAI category	138	63 (46)	105	39 (44)
Mean change in				
CDAI	138	-4.8 $\pm$ 11.8*	89	-7.1 $\pm$ 12.0*
HAQ-DI	154	-0.1 $\pm$ 0.5*	101	-0.2 $\pm$ 0.5*
Pain	154	-9.3 $\pm$ 25.1*	101	-13.5 $\pm$ 25.8*
Fatigue	153	-7.6 $\pm$ 27.3*	100	-12.5 $\pm$ 27.5*
MCID achievement in				
CDAI	138	57 (41)	89	43 (48)
HAQ-DI	154	55 (36)	101	39 (39)
Pain	154	68 (44)	101	53 (52)
Fatigue	153	65 (42)	100	49 (49)

^aMean $\pm$ SD or n (%). **P*<0.01 for improvement significantly different from zero.

of: Corrona, Taylor Blachley Employee of: Corrona, anna maniccia Shareholder of: AbbVie, Employee of: AbbVie, Dimitrios A Pappas Shareholder of: Corrona, Consultant of: AbbVie, Genentech, Novartis, Regeneron, and Roche Hellas, Employee of: Corrona

DOI: 10.1136/annrheumdis-2021-eular.170

POS0436

PATIENT CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB: THE OM1 RA REGISTRY

M. Bergman¹, N. Tundia², A. Bryant³, I. Topuria³, T. Brecht³, K. Dunlap², A. Gibofsky⁴, ¹Drexel University College of Medicine, Philadelphia, United States of America; ²AbbVie Inc, North Chicago, United States of America; ³OM1, Boston, United States of America; ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, United States of America

Background: Upadacitinib (UPA) has demonstrated efficacy in the treatment of rheumatoid arthritis (RA) in randomized controlled trials,¹⁻⁶ but there are limited data available on its real-world use and effectiveness in patients with RA.

Objectives: To describe the characteristics and clinical outcomes at 3 months among real-world patients with RA initiating UPA.

Methods: The data source for this study was the OM1 RA Registry, a subset of the OM1 Real-World Data Cloud (OM1, Inc, Boston, MA, US), a large, linked clinical and administrative dataset derived from medical and pharmacy claims, electronic medical record data, and death data. This analysis includes data collected in patients who initiated UPA during or after August 2019. Patients had ≥ 1 prescription for UPA (index date was first UPA prescription), were ≥ 18 years of age at index date, had ≥ 6 months of available data in the OM1 RA Registry prior to index date (ie, baseline period), ≥ 1 baseline disease activity measure, and ≥ 1 follow-up disease activity measure (3 or 6 months post-index). Disease activity was based on RAPID3 or CDAI. Multivariate analyses were conducted using a mixed-effects linear model adjusting for age, sex, and baseline scores. Outcomes were also assessed by therapy status (monotherapy or combination therapy) and targeted immunomodulator (TIM) use (naïve vs experienced).

Results: Inclusion criteria were met by 1,102 patients, of whom 620 were on monotherapy and 482 were on combination therapy at index. Mean age was 57.7 years, 83% were female, 75% had prior treatment with a biologic, and 47% had prior treatment with a Janus kinase inhibitor. Of 651 patients with known disease activity category, 113 (17%) were in low disease activity (LDA)/remission. At baseline, overall mean $\pm$ SD scores were 19.9 $\pm$ 12.3 for CDAI, 4.5 $\pm$ 2.4 for RAPID3, 5.7 $\pm$ 2.8 for pain, 5.2 $\pm$ 3.0 for fatigue, 3.1 $\pm$ 2.7 for MDHAQ Physician Global Assessment (PGA), 5.2 $\pm$ 2.8 for MDHAQ Patient Global Assessment (PtGA), and 3.1 $\pm$ 2.3 for MDHAQ Functional Index. At 3 months post-UPA initiation, mean (95% CI) change in CDAI was -5.1 (-7.5